Tag Archives: in vitro

Modulight Spotlights: LASER-SHARP RESEARCH – February 2025

February 17, 2025 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – February 2025 This month’s spotlight goes to A. Lepland and the teams at University of Tartu, Estonia and Veneto Institute of Oncology, Italy, who developed a new immunotherapy for triple negative breast cancer. This subtype of breast cancer is often very aggressive and notoriously difficult to treat as it lacks hormone receptors. In the new publication in Advanced Science, researchers developed a peptide-drug conjugate against tumor-promoting immune cells that suppress the immune response against tumor. The developed drug consists of Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – January 2025

January 22, 2025 by Modulight Content
No comments
   Modulight Spotlights: LASER-SHARP RESEARCH – January 2025 We are pleased to highlight this month a new study published in Cancer Immunology, Immunotherapy by Hisataka Kobayashi’s team at National Cancer Institute, NIH. They developed light-activated immunotherapy targeting a specific protein found on the surface of many cancer cells, called tissue factor. This therapy consists of antibody-photoabsorber conjugate that binds to cancer cell surface, and in response to near-infrared light, induces photochemical reaction that results in membrane destruction and immunogenic cell death. When this novel agent was Continue reading →

Self-Assembled Verteporfin Nanoparticles for Photodynamic and Light-Independent Therapy in Glioblastoma

September 28, 2024 by Modulight Content
No comments
Published in: Advanced NanoBioMed Research Authors: John A. Quinlan, Kaylin Baumiller, Anandita Gaur, Wen-An Chiou, Robert W. Robey, Michael M. Gottesman, Huang-Chiao Huang  Published in: Advanced NanoBioMed Research Authors: John A. Quinlan, Kaylin Baumiller, Anandita Gaur, Wen-An Chiou, Robert W. Robey, Michael M. Gottesman, Huang-Chiao Huang A nanosuspension of verteporfin, termed NanoVP, that requires no carriers is developed, permitting delivery of VP alone in an aqueous solution. NanoVP is produced by solvent–antisolvent precipitation, with dimethyl sulfoxide as the preferable solvent. The paper describes the characterization of NanoVP, including bioavailability and anticancer capacity in glioblastoma with ML6600 laser irradiation, as well as potontial of NanoVP for light-independent therapy.   Read Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – September 2024

September 23, 2024 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – September 2024 University of Maryland and Modulight have published together a new research study about the mechanisms of cancer drug resistance. Drug resistance is a leading cause of treatment failure and often has dramatic consequences for survival of cancer patients. Cancer cells have developed various ways to protect themselves from drugs. When several clinically used photoactive drugs were studied, it was shown that some of them were being actively pumped out by cancer cells, thus likely limiting the full therapeutic potential Continue reading →

Screening of photosensitizers-ATP binding cassette (ABC) transporter interactions in vitro

September 20, 2024 by Modulight Content
No comments
Published in: Cancer Drug Resistance Authors: Shruti Vig1, Payal Srivastava1,#, Idrisa Rahman1,2,#, Renee Jaranson1, Anika Dasgupta1, Robert Perttilä3, Petteri Uusimaa3, Huang-Chiao Huang1  Published in: Cancer Drug Resistance Authors: Shruti Vig1, Payal Srivastava1,#, Idrisa Rahman1,2,#, Renee Jaranson1, Anika Dasgupta1, Robert Perttilä3, Petteri Uusimaa3, Huang-Chiao Huang1 University of Maryland and Modulight have published together a new research study about the mechanisms of cancer drug resistance. Drug resistance is a leading cause of treatment failure and often has dramatic consequences for survival of cancer patients. Cancer cells have developed various ways to protect themselves from drugs. When several clinically used photoactive drugs were studied, it was shown that some of them were being actively pumped out by cancer cells, thus likely limiting the full therapeutic potential of these Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – June 2024

June 12, 2024 by Modulight Content
No comments
 Modulight Spotlights: LASER-SHARP RESEARCH – June 2024 A promising new therapy against viruses was developed at University of Manitoba and Theralase Technologies. Infectious agents are a global problem, causing millions of deaths every year. The study evaluated antiviral effectiveness of a cancer drug (Ruvidar), which is currently in clinical development for bladder cancer. When this drug was activated with green laser using Modulight’s ML6600, it resulted in a rapid elimination of many different human viruses. Impressively, it was >99% effective at low doses in inactivating human coronavirus, influenza Continue reading →

Ru(II) Oligothienyl Complexes with Fluorinated Ligands: Photophysical, Electrochemical, and Photobiological Properties

May 10, 2024 by Modulight Content
No comments
Published in: Inorganic Chemistry Authors: Houston D. Cole, Abbas Vali, John A. Roque III, Ge Shi, Alisher Talgatov, Gurleen Kaur, Antonio Francés-Monerris, Marta E. Alberto, Colin G. Cameron, Sherri A. McFarland  Published in: Inorganic Chemistry Authors: Houston D. Cole, Abbas Vali, John A. Roque III, Ge Shi, Alisher Talgatov, Gurleen Kaur, Antonio Francés-Monerris, Marta E. Alberto, Colin G. Cameron, Sherri A. McFarland A series of Ru(II) complexes were characterized and assessed for phototherapy effects toward cancer cells. Also activity in hypoxia was evaluated, with some of the compounds retaining partial activity in hypoxia. ML8500 was used for dosimetry studies, assessing impact of irradiance on the phototoxicity of Ru-4T with several different wavelengths. LEDs were used for Continue reading →

Near‐infrared photoimmunotherapy targeting PD‐L1: Improved efficacy by preconditioning the tumor microenvironment

April 26, 2024 by Modulight Content
No comments
Published in: Cancer Science Authors: Fuyuki F. Inagaki, Makoto Kano, Aki Furusawa, Takuya Kato, Ryuhei Okada, Hiroshi Fukushima, Seiichiro Takao, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi  Published in: Cancer Science Authors: Fuyuki F. Inagaki, Makoto Kano, Aki Furusawa, Takuya Kato, Ryuhei Okada, Hiroshi Fukushima, Seiichiro Takao, Shuhei Okuyama, Peter L. Choyke, Hisataka Kobayashi In this study, the efficacy of PD-L1-targeted NIR-PIT (photoimmunotherapy) with ML7710 was assessed in immune-competent tumor mouse models. PIT showed a significant therapeutic effect on the tumor models with high PD-L1 expression. Furthermore, it induced an abscopal effect on distant tumors and long-term immunological memory. Combination with interferon-gamma improved the treatment efficacy by increasing PD-L1 expression leading to more Continue reading →

Near-infrared photoimmunotherapy targeting Nectin-4 in a preclinical model of bladder cancer

March 31, 2024 by Modulight Content
No comments
Published in: Cancer Letters Authors: Hiroshi Fukushima, Seiichiro Takao, Aki Furusawa, Vladimir Valera Romero, Sandeep Gurram, Takuya Kato, Shuhei Okuyama, Makoto Kano, Peter L. Choyke, Hisataka Kobayashi  Published in: Cancer Letters Authors: Hiroshi Fukushima, Seiichiro Takao, Aki Furusawa, Vladimir Valera Romero, Sandeep Gurram, Takuya Kato, Shuhei Okuyama, Makoto Kano, Peter L. Choyke, Hisataka Kobayashi Enfortumab vedotin (EV), an antibody-drug conjugate (ADC) that targets Nectin-4, has shown promising results in the treatment of bladder cancer. The study investigated use of Nectin-4 targeting photoimmunotherapy in preclinical bladder cancer models. ML7710 was used as light source for activating the therapy in vitro and in vivo.   Read the article here

Phototruncation cell tracking with near-infrared photoimmunotherapy using heptamethine cyanine dye to visualise migratory dynamics of immune cells

March 14, 2024 by Modulight Content
No comments
Published in: eBioMedicine Authors: Hiroshi Fukushima, Aki Furusawa, Seiichiro Takao, Siddharth S. Matikonda, Makoto Kano, Shuhei Okuyama, Hiroshi Yamamoto, Peter L. Choyke, Martin J. Schnermann, Hisataka Kobayashi  Published in: eBioMedicine Authors: Hiroshi Fukushima, Aki Furusawa, Seiichiro Takao, Siddharth S. Matikonda, Makoto Kano, Shuhei Okuyama, Hiroshi Yamamoto, Peter L. Choyke, Martin J. Schnermann, Hisataka Kobayashi A new method called phototruncation-assisted cell tracking (PACT) can be used to noninvasively track migration of immune cells to understand anti-cancer immunity mechanisms. PACT is based on irreversible photo-induced truncation reaction, transforming Cy7 into Cy5 when exposed to NIR light (780 nm). PACT was used in this study to monitor spatiotemporal migration of immune cells between tumor and Continue reading →